How to appeal a Highmark asthma & severe allergies denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for asthma & severe allergies

Cited policy: BCBS Pharmacy Policy — Epinephrine Auto-Injector Brand vs Generic

Documented anaphylaxis or high risk (food / venom / idiopathic). Patient/caregiver trained on specific device. Weight-appropriate dose (0.15 mg pediatric >=15 kg, 0.3 mg >=30 kg).

How Highmark denies asthma & severe allergies — and how to counter it

Where Highmark pushes back: 1) Use authorized generic / Adrenaclick generic; 2) No anaphylaxis documentation.

Counter-arguments that hold up: Document device-specific counseling. Teva recalls 2018-2020 (FDA shortage list). Auvi-Q voice-prompt benefit in caregiver/childcare. School/daycare stocking laws specifying EpiPen by name. Needle length 14.3mm for higher-BMI. AAAAI/ACAAI Anaphylaxis Practice Parameter 2020 (Shaker JACI 2020). For Neffy: needle-phobia documentation + Aug 9, 2024 approval.

What Highmark typically denies for asthma & severe allergies

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For asthma & severe allergies, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the asthma & severe allergies treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Xolair
• Dupixent (asthma)
• Nucala
• Fasenra
• Cinqair
• Tezspire

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.